Kyntra Bio Inc

KYNB Healthcare Biotechnology

In the quarter to June 2026, revenue fell 209.4%, EPS grew 257.5% and free cash flow fell 131.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.85 0.51 −9.51%
Market cap
$21.7M
P/E
0.1×
Fwd P/E
−0.5×
Dividend yield
—
F-score
5/9
Altman Z
−20.33
Beneish M
−4.57
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— 5 5 5
ROE
(189.86%) (165.18%) (144.04%) (157.83%)
ROA
107.44% 109.81% 119.06% 131.26%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
221.30% 262.71% 223.39% 301.38%
Average Days of Receivables
5.32 12.24 247.29 27.43
Free Cash Flow per Share
(4.18) (1.19) (5.28) (9.40)
Free Cash Flow
(16.88) (4.81) (21.38) (38.05)
Other line items

Show all line items

Columns are period end dates